Mortality rates in elderly patients who take different angiotensin- converting enzyme inhibitors after acute myocardial infarction: A class effect?

Annals of Internal Medicine

Volumn 141, Issue 2, 2004, Pages

  Pilote, Louise ^a   Abrahamowicz, Michal ^a   Rodrigues, Eric ^a   Eisenberg, Mark J ^a   Rahme, Elham ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; LISINOPRIL; NITRATE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; WARFARIN;

AGED; AGING; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DEMOGRAPHY; DRUG DOSE REGIMEN; FEMALE; HEART INFARCTION; HOSPITAL; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONBIOLOGICAL MODEL; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL RATE; CHEMICAL STRUCTURE; CHEMISTRY; DATA BASE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DATABASES; FEMALE; HUMANS; MALE; MOLECULAR STRUCTURE; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 85047171677     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-141-2-200407200-00008     Document Type: Article

References (49)

1. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821-8. [PMID: 8104270]
2. Foy SG, Crozier IG, Turner JG, Richards AM, Frampton CM, Nicholls MG, et al. Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the "PRACTICAL" study). Am J Cardiol. 1994;73:1180-6. [PMID: 8203335]
3. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994;343:1115-22. [PMID: 7910229]
4. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet. 1995;345:686-7. [PMID: 7885123]
5. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669-85. [PMID: 7661937]
6. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77. [PMID:1386652]
7. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670-6. [PMID: 7477219]
8. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet. 1999;354:1202-4. [PMID: 10513728]
9. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-46. [PMID: 9385294]
10. Sica DA. Class effects of angiotensin-converting enzyme inhibitors. Am J Manag Care. 2000;6:S85-108; quiz S109-11. [PMID: 10977451]
11. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302. [PMID: 2057034]
12. Khalil ME, Basher AW, Brown EJ Jr, Alhaddad IA. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol. 2001;37:1757-64. [PMID: 11401108]
13. Voors AA, Kingma JH, van Gilst WH. Drug differences between ACE inhibitors in experimental settings and clinical practice. J Cardiovasc Risk. 1995;2:413-22. [PMID: 8749268]
14. Furberg CD. Class effects and evidence-based medicine. Clin Cardiol. 2000;23:IV15-9. [PMID: 10894451]
15. Wooltorton E. Bayer pulls cerivastatin (Baycol) from market. CMAJ. 2001;165:632. [PMID: 11563216]
16. Kizer JR, Kimmel SE. Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. Arch Intern Med. 2001;161:1145-58. [PMID: 11343438]
17. Michalewicz L, Messerli FH. Cardiac effects of calcium antagonists in systemic hypertension. Am J Cardiol. 1997;79:39-46; discussion 47-8. [PMID: 9186066]
18. Abrams J. The role of nitrates in coronary heart disease. Arch Intern Med. 1995;155:357-64. [PMID: 7848018]
19. Kakinoki S, Nomura A, Takechi S, Kitabatake A. Effects of short- and long-acting calcium channel blockers on the relationship between blood pressure and physical activity. Am J Hypertens. 2001;14:66-9. [PMID: 11206682]
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. [PMID: 10639539]
21. Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ. 2003;168:553-7. [PMID: 12615747]
22. Pilote L. Ramipril use in Canada: HOPE or HYPE? CMAJ. 2003;168:568-9. [PMID: 12615751]
23. Pilote L. More than just hype [Letter]. CMAJ. 2003;168:1647-48.
24. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. Can J Cardiol. 1996;12:127-37. [PMID: 8605634]
25. Pilote L, Lavoie F, Ho V, Eisenberg MJ. Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995. CMAJ. 2000;163:31-6. [PMID: 10920727]
26. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145:438-44. [PMID: 12660666]
27. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society B. 1972;34:187-220.
28. Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003;115:473-9. [PMID: 14563504]
29. Levy AR, Tamblyn RM, Fitchett D, McLeod PJ, Hanley JA. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol. 1999;15:1277-82. [PMID: 10579743]
30. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley; 1980.
31. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
32. Collett D. Modelling Survival Data in Medical Research. London: Chapman and Hall; 1994.
33. Reid N, Crépeau H. Influence functions for proportional hazards regression. Biometrika. 1985;72:1-9.
34. Greenland S. Basic methods for sensitivity analysis of biases. Int J Epidemiol. 1996;25:1107-16. [PMID: 9027513]
35. Leonetti G, Cuspidi C. Choosing the right ACE inhibitor. A guide to selection. Drugs. 1995;49:516-35. [PMID: 7789286]
36. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-20. [PMID: 9577953]
37. Giles TD, Katz R, Sullivan JM, Wolfson P, Haugland M, Kirlin P, et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol. 1989;13:1240-7. [PMID: 2539403]
38. Piepho RW. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000;57 Suppl 1:S3-7. [PMID: 11030016]
39. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97:2202-12. [PMID: 9631869]
40. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575-81. [PMID: 108213601]
41. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001;87:1058-63. [PMID: 11348602]
42. Oosterga M, Voors AA, Pinto YM, Buikema H, Grandjean JG, Kingma JH, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol. 2001;87:542-6. [PMID: 11230836]
43. PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction: study rationale and design. Cardiovasc Drugs Ther. 2000;14:671-9. [PMID: 11300369]
44. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678-84. [PMID: 1495520]
45. Gavazzi A, Marioni R, Campana C, Montemartini C. Comparative trial of quinaptil versus captopril in mild to moderate congestive heart failure. Quinapril/Captopril Congestive Heart Failure Study Group. J Hypertens Suppl. 1994;12:S89-93. [PMID: 7965279]
46. Bach R, Zardini P. Long-acting angiotensin-converting enzyme inhibition: once-daily lisinopril versus twice-daily captopril in mild-to-moderate heart failure. Am J Cardiol. 1992;70:70C-77C. [PMID: 1329477]
47. Byar DP. Problems with using observational databases to compare treatments. Stat Med. 1991;10:663-6. [PMID: 20576631
48. Tamblyn R, Abrahamowicz M. Drug utilization patterns. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. West Sussex, United Kingdom: J Wiley; 1998:1235-47.
49. Abrahamowicz M, MacKenzie T, Esdaile JM. Time-dependent hazard ratio: modeling and hypothesis testing with application in lupus nephritis. Journal of the American Statistical Association. 1996;91:1432-9.